Spironolactone in the Treatment of Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 743 participants.
Also called NCT04727073
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 743 participants
- Sponsor
- Registry
-
NCT04727073
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, France, Germany, Netherlands, Serbia
- Registry status
- Terminated
Technical summary
Registry record NCT04727073. Randomized; double masking; primary purpose treatment. Start 2018-11-01 (actual); primary completion 2024-10-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Spironolactone in the Treatment of Heart Failure
- Acronym
- SPIRIT-HF
- Condition
- Heart Failure with Mid-range Ejection Fraction
- Intervention (Drug)
- Experimental: Spironolactone
- Intervention (Drug)
- Placebo Comparator
- Lead sponsor
- Charite University, Berlin, Germany
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator
- Echo Core Lab Berlin
- Collaborator
- University of Göttingen
- Collaborator
- University Medicine Greifswald
- Collaborator
- Ludwig-Maximilians - University of Munich
- Collaborator
- Institute for Cardiovascular Computer-assisted Medicine, Charité
- Collaborator
- Coordinating Centre for Clinical Trials, Charité
Record details
- Record id
cardio:ct-nct04727073- Content hash
e223626ebc4b3fe2a5249367854994ef59b9d40a309e3a9a735af431ce089416